Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002218
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Phase I Maximum Tolerated Dose Study of CI-1012 in Late-Stage HIV Patients
Sponsor:
Parke-Davis
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Phase I Maximum Tolerated Dose Study of CI-1012 in Late-Stage HIV Patients
Status:
COMPLETED
Status Verified Date:
1998-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine the maximum tolerated dose of CI-1012 in late-stage HIV-1-infected patients To determine the antiretroviral activity of CI-1012 when added to combination therapy To assess the multiple-dose pharmacokinetic characteristics of CT-1012 when added to combination therapy To assess the effect of CI-1012 on the pharmacokinetics of other antiretroviral agents
Detailed Description:
Doses are escalated based on safety assessments As soon as a dose meets the criteria for tolerated or not tolerated doses are escalated or terminated respectively All patients are treated for 2 weeks with follow-up visits scheduled 1 week and 1 month post-treatment
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: